MEDIPAL HOLDINGS CORPORATION
7459・Prime Market・Wholesale Trade
Business
MEDIPAL HOLDINGS CORPORATION is a holding company for a healthcare wholesale group comprising 32 subsidiaries and 19 affiliated companies. It operates three segments: the Prescription Pharmaceuticals Wholesale Business (net sales of ¥2,466,109 million), which supplies prescription pharmaceuticals, medical devices, and clinical diagnostic reagents to hospitals and dispensing pharmacies; the Cosmetics, Daily Necessities & OTC Pharmaceuticals Wholesale Business (net sales of ¥1,237,846 million), centered on PALTAC, which handles cosmetics and daily necessities for drugstores and other retailers; and the Veterinary Pharmaceuticals & Food Processing Materials Wholesale Related Business (net sales of ¥117,328 million), which deals in veterinary pharmaceuticals and food processing materials. Consolidated net sales reached ¥3,817,354 million, with the company serving as a distribution network functioning as social infrastructure.
Business Model
The core model is wholesale: purchasing products from pharmaceutical and cosmetics manufacturers and supplying them to hospitals, dispensing pharmacies, drugstores, and others. The company leverages 14 ALCs (Area Logistics Centers, high-functionality logistics centers) nationwide and approximately 2,000 AR (Assist Representatives, pharmaceutical specialist sales staff) to provide stable supply and the added value of information provision. The gross profit margin is thin at 6.84%, but profitability is secured through large-scale transaction volumes and logistics efficiency. The company aims to improve profitability by expanding specialty pharmaceuticals and high-value-added products.
Company Strengths
Mediceo launched Tokyo ALC in January 2026, bringing the group's nationwide network to 14 ALC (Area Logistics Center) sites. Medisquet obtained ISO9001 certification at 9 ALC sites in August 2025, achieving GDP-compliant, high-quality logistics. Equipped with BCP measures, the company has built a crisis-resilient logistics platform that serves as social infrastructure difficult for competitors to replicate, underpinning the stable supply of pharmaceuticals.
Approximately 2,000 AR (Assist Representatives), comprised of MR certification exam passers, pharmacists, and others, have specialized into roles such as "Women's Coordinators" focused on women's clinical departments, "RD-MR" specializing in rare diseases, and "NS-MR" specializing in neurological and psychiatric disorders, developing a regional healthcare coordinator function that connects medical institutions, dispensing pharmacies, and local governments. This has become a unique sales asset amid growing demand for partnerships from pharmaceutical manufacturers and biotech ventures.
The company holds three segments: Prescription Pharmaceuticals Wholesale Business (net sales of ¥2,466,109 million), Cosmetics & Daily Necessities Wholesale (net sales of ¥1,237,846 million), and Veterinary Pharmaceuticals & Food Processing Materials (net sales of ¥117,328 million). This diversifies risks associated with regulatory changes or demand fluctuations in any single market, while each segment has distinct growth drivers. A robust financial base—with zero outstanding borrowings and an overdraft facility of ¥184.5 billion set up—supports portfolio expansion.
ENVALITH's Perspective
Performance Trend
Revenue rose over five consecutive fiscal years from ¥3,290,921 million in FY2022 (ending March 2022) to ¥3,817,354 million in FY2026 (ending March 2026) (+4.0% in FY2026). Operating profit declined from ¥55,609 million in FY2025 (ending March 2025) (a record-high level) to ¥53,182 million in FY2026 (ending March 2026) (-4.4%). This was due to an increase in business investment costs and other expenses (+¥2,916 million) and rising personnel and logistics costs in the Cosmetics, Daily Necessities & OTC Pharmaceuticals Wholesale Business. On the other hand, recurring profit increased substantially to ¥75,723 million (+16.0%), driven by a swing to profit in equity-method investment gains (from -¥3,768 million in the previous period to +¥3,907 million), ¥4,329 million in gains from investment partnership operations, and ¥21,347 million in gains on sale of investment securities. Profit attributable to owners of parent was ¥42,534 million (+5.6%). For FY2027 (ending March 2027), the company forecasts revenue of ¥3,944,000 million (+3.3%), operating profit of ¥55,000 million (+3.4%), recurring profit of ¥71,500 million (-5.6%), and net profit of ¥39,000 million (-8.3%), with a decline in profit expected due to the absence of extraordinary gains and other factors.
Growth Strategy
Advancing wholesale transformation—including the full consolidation of PALTAC—under the five growth strategies of the "MEDIPAL Mid-term Vision 2027"
Commenced a tender offer in May 2026 (¥6,650 per share, total purchase amount of approximately ¥192,456 million). By integrating the rigorous supply capabilities required for pharmaceuticals wholesale with the efficient multi-item supply capabilities of daily necessities wholesale, the company aims to create new consumer-centric distribution value. Earnings forecasts following full consolidation will be announced at an appropriate time.
The Tokyo ALC (the group's 14th ALC facility) commenced operations in January 2026. Medisquet obtained ISO9001 certification at 9 ALC facilities, providing high-quality logistics compliant with GDP guidelines. The company is also working to create new revenue opportunities by accepting logistics outsourcing from external companies.
In January 2026, MP Agro acquired all shares of Signi HD (a veterinary hospital-oriented e-commerce business), consolidating it into the group. The company aims to expand business in the agro-foods domain by strengthening sales to veterinary hospitals nationwide and expanding e-commerce sales channels. The company plans to accelerate synergy creation with Signi in FY2027 (ending March 2027).
JR-446, a treatment for Mucopolysaccharidosis Type IIIB, received orphan drug/rare disease drug designation from the FDA, the European Commission, and the Ministry of Health, Labour and Welfare. A licensing agreement for the overseas commercialization of JR-479, a treatment candidate for GM2 gangliosidosis, was also concluded, advancing the concretization of the overseas expansion strategy.
PALTAC launched the BtoB matching site "Nice2meet" in March 2026, facilitating online business negotiations between manufacturers and retailers. The company established the Product Registry Service, a new company for unified management of product information in collaboration with Arata and Planet, promoting efficiency across the entire industry. The company is also strengthening demand capture through the utilization of purchasing data.
Last updated: July 19, 2026